Journal of Clinical Oncology

A comparative analysis of complication rates in urinary diversions: Exploring the impact of contemporary surgical trends.

751 Background: Historically, outcomes have been similar among patients undergoing continent (CD) and incontinent diversion (ID) at time of radical cystec...

Whole-slide multiplexed tissue imaging of prostate adenocarcinoma to investigate immune niches in high- versus low-grade tumors.

224 Background: The tumor-immune microenvironment (TME) is crucial in the progression of prostate cancer (PCa), yet little is known about its spatial orga...

Impact of perioperative acute kidney injury on future renal outcomes in patients who undergo radical cystectomy: A multi-institutional retrospective cohort study.

879 Background: Acute kidney injury (AKI) is one of the frequent complications in patients who undergo radical cystectomy (RC). Although AKI has been repo...

Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting.

470 Background: Multiple approved immunotherapy (IO)-based combination regimens have demonstrated efficacy as first-line (1L) tx for mRCC, but have also s...

Patterns of split-dose gemcitabine and cisplatin (GC) use in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a 10-country physician survey.

699 Background: Gemcitabine + cisplatin (GC) is a highly effective treatment for la/mUC. For patients who are ineligible for standard GC, split-dose GC is...

Comparing progression following systemic and tumor-directed therapy for <i>de novo</i> versus recurrent PSMA PET–defined oligo-M1 prostate cancer: A pooled analysis of SOLAR and SATURN clinical trials.

64 Background: Therapeutic strategies for oligometastatic castration sensitive prostate cancer (omCSPC) combining treatment of the primary and metastases...

Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.

658 Background: In the phase 3, randomized, double-blind CheckMate 274 trial, adjuvant NIVO demonstrated statistically significant and clinically meaningfu...

Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).

551 Background: Combinations of therapies with VEGFR-TKI (TKI) and anti-PD1/PDL1 immunotherapy (IO) are considered the standard of care for first line tre...

Digital physiological monitoring for personalized prediction of physical function and fatigue in men with castration sensitive prostate cancer.

124 Background: Androgen deprivation therapy (ADT) associated fatigue and functional impairment presents challenges to patient quality of life (QOL) and t...

Phase 1 dose escalation (DEs) &amp; expansion (DEx) study to evaluate the safety &amp; efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).

Long follow-up quality of life outcomes from an investigator-initiated randomized trial of enzalutamide versus abiraterone plus prednisolone in docetaxel-untreated castration-resistant prostate cancer.

52 Background: Head-to-head comparison between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) demonstrated similar survival benefit for castra...

Association of clinical characterization of renal cell carcinoma (RCC) with merlin protein deficiency and biallelic loss of <i>NF2</i> .

506 Background: Neurofibromin-2 (NF2) is a tumor suppressor gene that encodes the scaffolding protein merlin and is commonly mutated in rare R...

Decipher risk stratification of radiorecurrent prostate cancer: Correlative analysis of the F-SHARP trial of salvage reirradiation.

419 Background: A third of patients with biochemical recurrence after radiation (RT) have intraprostatic radiorecurrence (IPR) on PSMA PET/CT. Patients wi...

Incidence of EMBARK and EAU high-risk biochemical recurrence and prostate cancer mortality: A real-life population-based study.

372 Background: The EMBARK trial proved the efficacy of enzalutamide plus leuprolide in patients with prostate cancer (PCa) who have had high-risk biochem...

Genome-wide burden survival tests for patients with metastatic prostate cancer on androgen receptor-targeted therapies in the Million Veterans Program dataset.

251 Background: Literature suggests various genes influence metabolism and treatment response in prostate cancer. While the androgen receptor gene is the...

Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial.

TPS287 Background: Mevrometostat (PF-06821497) is a potent, selective inhibitor of the histone methyltransferase enhancer of zeste 2 (EZH2), which is cano...

Outcomes of different therapeutic modalities for patients with metachronous oligometastatic renal-cell carcinoma (RCC): Analyses of a single-institution database.

553 Background: There is limited data in the literature concerning the management of patients (pts) with metachronous oligometastatic RCC. This study aime...

Use of urinary cell-free DNA methylation assay to identify tumor fraction for early detection and recurrence monitoring in urothelial carcinoma.

844 Background: Urothelial carcinoma (UC) remains one of the most common urologic cancers, presenting challenges in both initial diagnosis and follow-up d...

Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.

152 Background: In ARASENS, darolutamide (DARO) + androgen deprivation therapy (ADT) + docetaxel (DOC) significantly reduced risk of death by 32.5% vs pla...

A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer.

831 Background: Long non-coding RNA (lncRNA)-based genomic profiling has suggested utility to identify a distinct tumor subgroup corresponding to a favora...

Comparative assessment of pre- and post-COVID-19 pandemic nephrectomy outcomes for renal cell carcinoma: Analysis of the ACS-NSQIP registry.

466 Background: The COVID-19 pandemic placed significant strain on healthcare systems in the U.S. Public health directives aimed at mitigating the spread...

ProstACT GLOBAL: A phase 3 study of ¹⁷⁷ Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.

TPS303 Background: The treatment of advanced prostate cancer (PC) is challenging, with undesirable side effects that impact patient quality of life. Radio...

An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.

328 Background: Prostate cancer is the most common male malignancy. Current diagnostic methods using single TPSA and PHI lack specificity. Some researches...

Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma.

558 Background: Nivo/ipi is a standard of care first-line (1L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC) but its role i...

A liquid biopsy-based proteomic assay to identify circulating tumor cell (CTC) –derived druggable targets in cancer patients.

258 Background: Cancers are often thought of as a disease of a specific tissue; however, the drugs designed to fight them are tissue agnostic. These drugs...